Chordate Medical at IHC 2023: “Great Interest in Ozilia™”
20 September 2023
Menu
The public offer documents are available in Swedish when no translation exists.
2022-12-21
Appilcation Form for subscription of shares without rights
2022-02-10
Company description
2021-09-27
Application form for subscription of shares through the exercise of warrants (Swedish)
2020-08-25
Teaser
Inbjudan till teckning av units
2019-10-28
Anmälningssedel
2019-10-23
Villkor för teckningsoptioner
Inbjudan till teckning av Units i Chordate Medical
Teaser Företrädesemission oktober 2019
2019-04-03
Anmälningssedel för teckning av units i Chordate utan företrädesrätt
2019-03-22
Villkor och anvisningar
Teaser
2018-05-09
Inbjudan till teckning av Units i Chordate Medical maj 2018 – Teaser
Inbjudan till teckning av Units i Chordate Medical Företrädesemission maj 2018 – Memorandum
2017-03-02
Listningsmemorandum inför notering på NGM Nordic MTF Chordate Medical
2017-01-31
Inbjudan till teckning av aktier i Chordate Medical Holding
Välkommen att teckna aktier i Chordate Notering på NGM Nordic MTF – Emissionsfolder
2022-12-21
We are a Swedish medical technology company listed on Nasdaq First North Growth Market.
Chordate has spent more than 10 years developing the treatment Ozilia™ Migraine, which is based on Kinetic Oscillation Stimulation, a technique for treating rhinitis and migraine. We have a patent on Ozilia™ in the EU and the United States, as well as many other countries.
We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical’s share is listed on the Nasdaq First North Growth Market (ticker: CMH).